Compare Inovio Pharmaceuticals Inc (INO) vs Invesco Ltd. (IVZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Invesco Ltd. — how do they compare? Inovio Pharmaceuticals Inc trades at $1.08 (market cap $89.27M), while Invesco Ltd. trades at $29.68 (market cap $13.15B). The key difference: Invesco Ltd. is far larger — about 147.3× Inovio Pharmaceuticals Inc's market cap, and Invesco Ltd. pays a 2.9% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | IVZ | |
|---|---|---|
Market Cap | $89.27M | $13.15B |
Sector | Health | Financials |
52-Week High | $2.87 | $30.30 |
52-Week Low | $1.05 | $20.20 |
Enterprise Value | $60.28M | $23.39B |
Dividend Yield | — | 2.9% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Invesco Ltd.
Invesco provides investment-management services to retail (65% of managed assets) and institutional (35%) clients. At the end of August 2022, the firm had $1.416 trillion in assets under management spread among its equity (47% of AUM), balanced (5%), fixed-income (22%), alternative investment (14%), and money market (12%) operations. Passive products account for 32% of Invesco's total AUM, including 56% of the company's equity operations and 13% of its fixed-income platform. Invesco's U.S. retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside the U.S., with close to one third of its AUM sourced from Canada (2%), the U.K. (4%), continental Europe (11%), and Asia (15%).
Read more on IVZ →
